In 2014, two phase II clinical studies reported rapid, impressive increases in BMD in women with low bone mass who were treated with sclerostin inhibitors for 1 year. The antifracture efficacy and tolerability of these new, bone-building therapies are currently being investigated in phase III clinical trials.
This is a preview of subscription content, log in via an institution to check access.
References
Tsai, J. N. et al. Teriparatide and denosumab, alone or combined in women with postmenopausal osteoporosis: the DATA study randomized trial. Lancet 382, 50–56 (2013).
Leder, B. Z. et al. Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (the DATA extension study): a randomized controlled trial. J. Clin. Endocrinol. Metab. 99, 1694–1700 (2014).
Ke, H. Z., Richards, W. G., Li, X. & Ominsky, M. S. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr. Rev. 33, 747–783 (2012).
Moester, M. J., Papapoulos, S. E., Lowik, C. W. & van Bezooijen, R. L. Slerostin: current knowledge and future perspectives. Calcif. Tissue Int. 87, 99–107 (2010).
Li, X. et al. Sclerostin antibody treatment increases bone formation, bone mass and bone strength in a rat model of postmenopausal osteoporosis. J. Bone Miner. Res. 24, 578–588 (2009).
Ominsky, M. S. et al. Two doses of sclerostin antibody in cynomologous monkeys increase bone formation, bone mineral density and bone stength. J. Bone Miner. Res. 25, 948–959 (2010).
Padhi, D., Jang, G., Struch, B., Fang, L. & Posrar, E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J. Bone Miner. Res. 26, 19–26 (2011).
Recker, R. et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J. Bone Miner. Res. http://dx.doi.org/10.1002/jbmr.2351.
McClung, M. R. et al. Romosozumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 370, 412–420 (2014).
Ominsky, M. S., Niu, Q.-T., Li, C., Li, X. & Ke, H. Z. Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody. J. Bone Miner. Res. 29, 1424–1430 (2014).
Acknowledgements
The author's studies on sclerostin are supported by and carried out within the FP7 programme TALOS, which is funded by the European Commission (Grant Number: TALOS:Health-F2-2008-201,099).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author has received consulting fees and speaker honoraria from Amgen and UCB.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Papapoulos, S. New bone-forming treatments for osteoporosis. Nat Rev Endocrinol 11, 69–70 (2015). https://doi.org/10.1038/nrendo.2014.214
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2014.214
- Springer Nature Limited
This article is cited by
-
Comparison of unipedicular and bipedicular kyphoplasty for treating acute osteoporotic vertebral compression fractures in the lower lumbar spine: a retrospective study
BMC Musculoskeletal Disorders (2023)
-
New anabolic therapies for osteoporosis
Internal and Emergency Medicine (2017)
-
Sclerostin Inhibition in the Management of Osteoporosis
Calcified Tissue International (2016)
-
From disease to treatment: from rare skeletal disorders to treatments for osteoporosis
Endocrine (2016)
-
Association between teriparatide treatment persistence and adherence, and fracture incidence in Taiwan: analysis using the National Health Insurance Research Database
Osteoporosis International (2016)